about
Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural AnalysisTransthyretin complexes with curcumin and bromo-estradiol: evaluation of solubilizing multicomponent mixturesX-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitorsN-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic ActivityA new crystal form of human transthyretin obtained with a curcumin derived ligandSynthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR)Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 InhibitorsComparison of helical scan and standard rotation methods in single-crystal X-ray data collection strategies.TTR fibril formation inhibitors: is there a SAR?Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells.Allosteric inhibition of [(125I)] ET-1 binding to ET(A) receptors by aldoxime and hydroxamic acid derivatives.Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring.7-Nitrobenzofurazan (NBD) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A(3) adenosine receptors.Conformationally restrained analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2',5'-morpholines].Spirotetrahydronaphthalene analogues of sympathomimetic catecholamines. Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1 (2H)-3'-piperidines].Synthesis and affinity for serotonin and dopamine transporters of some benzophenone oxime ether derivatives.Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.3-[(Aryl)(4-fluorobenzyloxy)methyl]piperidine derivatives: high-affinity ligands for the serotonin transporter.Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oTargeting Different Transthyretin Binding Sites with Unusual Natural Compounds.A new D₂ dopamine receptor agonist allosterically modulates A(2A) adenosine receptor signalling by interacting with the A(2A)/D₂ receptor heteromer.Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic StudiesSynthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compoundsTricyclic Sulfonamides Incorporating Benzothiopyrano[4,3-c]pyrazole and Pyridothiopyrano[4,3-c]pyrazole Effectively Inhibit α- and β-Carbonic Anhydrase: X-ray Crystallography and Solution Investigations on 15 IsoformsSynthesis, molecular docking and binding studies of selective serotonin transporter inhibitorsDesign, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 InhibitorsN-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for OsteoarthritisCarbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamatesN-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMPTafamidis (Vyndaqel): A Light for FAP PatientsSynthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cellsSynthesis and antimicrobial properties of cephalosporin derivatives substituted on the C(7) nitrogen with arylmethyloxyimino or arylmethyloxyamino alkanoyl groupsSynthesis and aldose reductase inhibitory activity of new N-(benzyloxy) glycine derivativesThe [(Methyloxy)imino]methyl Moiety as a Bioisoster of Aryl. A Novel Class of Completely Aliphatic .beta.-Adrenergic Receptor AntagonistsDesign and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles
P50
Q27656578-3C1992E8-5DF0-469F-BC9E-BD58183BFF41Q27695622-54E2875C-72D1-43B3-8A7E-2FFA48AA1489Q27701718-77940795-2676-449A-8E6F-2401FFBC1B99Q27701780-A33DD6B1-BA3B-4D31-A307-2EA83086EA32Q27703670-CA57BC7B-60C0-4509-A3C6-953035E1ED80Q27704552-1D42613A-17F8-40E7-8572-66DC54231654Q27715081-927DBD10-6983-4CB5-8F48-D586EED44C6EQ31150941-D81C5F21-A01D-4741-90F2-5A25353CA3D8Q37999494-98A1FD7C-98B8-4945-84D9-2B8D8FB5FAF2Q39094755-E9D9B01A-6BC5-4B46-9CEA-9441F2CFFD81Q39735845-C1B898A2-4A97-4FF6-93A3-70670877203CQ39808966-D8BAF8E1-66DC-4D67-AE6D-1FD25A7CF7DCQ39955068-86631E73-86CF-42EA-B5DD-FF652A6EA283Q40666140-42C2DC1A-6F36-4602-8FD4-EAA8762B8853Q43803537-76FB3CED-9B1B-46C3-B574-14FE626C2837Q43884074-A66D4B9E-5E68-4D78-88EB-53B200E018F5Q43989502-E3D17A65-4F80-4498-BD01-01A5FCA20208Q44588392-D0BE13D5-23F2-46F2-824A-C39E278D05A7Q45788712-A4AAAF2A-A983-4C6D-815C-87FB186B7CB1Q46970780-2E06182A-8476-4FD6-A522-E78D22E466FDQ48254798-39D9DFAD-8FDA-4B07-AA24-22B1EEEC883DQ50855015-EAF3C01C-2E73-4592-ABEC-84E4E68E12DBQ51762192-E99304B8-72C6-439C-B590-FF6F9EA69DD4Q58308020-FC843F6F-1CAA-4920-A298-91B7F696EEF8Q58308093-89473654-78B6-463F-A831-C16CA6BC1366Q58308152-8A1D63D3-0F43-4BAB-A942-DE505398BD0CQ58308174-D3AF5605-5998-4CF3-9C22-A86EB10E4A5BQ58308192-279C472B-C806-4B73-A6F6-C92DA84E1380Q58308205-C0561AE5-D1C4-4AB9-9509-4427586AE338Q58308238-AA920347-80FA-403D-8839-891D642AE5BBQ58308267-82477BAB-442A-488F-ACAD-92B318BDBD0FQ58960285-0A3748FC-37CA-45F4-9644-C511E3D444DDQ58960296-D8C95140-B189-4B93-A241-AEB3AB0FF638Q58960314-F4A4562B-61B3-495C-930E-7B8A992F214FQ58960319-19A03025-4243-4476-B3C5-8542EF04640AQ58960559-BF14E201-05AD-4389-9BC6-CD6D88C8FCA6Q90845998-7A8B9C1A-63FA-4B2B-9704-14C19AF0C3F8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Susanna Nencetti
@ast
Susanna Nencetti
@en
Susanna Nencetti
@es
Susanna Nencetti
@nl
type
label
Susanna Nencetti
@ast
Susanna Nencetti
@en
Susanna Nencetti
@es
Susanna Nencetti
@nl
altLabel
S Nencetti
@en
SUSANNA NENCETTI
@en
prefLabel
Susanna Nencetti
@ast
Susanna Nencetti
@en
Susanna Nencetti
@es
Susanna Nencetti
@nl
P106
P1153
6602098803
P21
P31
P496
0000-0002-3547-7277